Cumberland Pharmaceuticals

CompanyUnited States

RORWikidata

Cumberland Pharmaceuticals develops 5 assets, the furthest approved (Kristalose in acute and chronic constipation). Mostly small molecule acting on AVPR1A, AVPR2 and TBXA2R; based in the United States.

5
Assets
Furthest stage
Approved
34
Trials
8
Signals

Pipeline

5
  • Kristalose

    Synthetic non-absorbable disaccharide osmotic laxative promoting intestinal motility.

    Approved, Small molecule, acute and chronic constipation, anal fissure (Phase 3)

  • Talicia

    Approved, Small molecule, Helicobacter pylori infection

  • Vaprisol

    Blocks vasopressin V1A and V2 receptors, promoting free-water excretion and reducing vasopressin-mediated vasoconstriction.

    Approved, Small molecule, AVPR1A, AVPR2, euvolemic and hypervolemic hyponatremia, acute decompensated heart failure (Phase 3)

2 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms4
  • Trials44
  • Deals3
  • People6
  • Signals13
  • Similar companies6

Intelligence